Measurement issues related to lipoprotein heterogeneity

American Journal of Cardiology

Volumn 90, Issue 8 SUPPL., 2002, Pages 22-29

  Otvos, James D ^a   Jeyarajah, Elias J ^a   Cromwell, William C ^a  

^a LIPOSCIENCE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ACCURACY; ANALYTIC METHOD; ANALYTICAL PARAMETERS; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; HIGH RISK POPULATION; HUMAN; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW;

EID: 0037126373     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02632-2     Document Type: Article

References (31)

1. Fredrickson D.S., Levy R.I., Lees R.S. Fat transport in lipoproteins - an integrated approach to mechanisms and disorders. N Engl J Med. 276:1967;148-156.
2. Beisiegel U., St. Clair R.W. An emerging understanding of the interactions of plasma lipoproteins with the arterial wall that leads to the development of atherosclerosis. Curr Opin Lipidol. 7:1996;265-268.
3. Williams K.J., Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 15:1995;551-561.
4. Castelli W.P., Garrison R.J., Wilson P.W.F., Abbott R.D., Kalousdian S., Kannel W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels the Framingham Study . JAMA. 256:1986;2835-2838.
5. Austin M.A., Hokanson J.E., Edwards K.L. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 81:1998;7B-12B.
6. Sniderman A., Shapiro S., Marpole D., Malcolm I., Skinner B., Kwiterovich P.O. The association of coronary atherosclerosis and hyperapobetalipoproteinemia (increased protein but normal cholesterol content in human plasma low density lipoprotein). Proc Natl Acad Sci USA. 97:1980;604-608.
7. van Lennep J.E., Westerveld H.T., van Lennep H.W., Zwinderman A.H., Erkelens D.W., van der Waal E.E. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol. 20:2000;2408-2413.
8. Gotto A.M., Whitney E., Stein E.A., Shapiro D.R., Clearfield M., Weis S., Jou J.Y., Langendorfer A., Beere P.A., Watson D.J., Downs J.R., de Cani J.S. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 101:2000;477-484.
9. Lamarche B., Despres J.P., Moorjani S., Cantin B., Dagenais G.R., Lupien P.J. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec Cardiovascular Study). Am J Cardiol. 75:1995;1189-1195.
10. Waldius G., Jungner I., Holme I., Aastveit A.H., Kolar W., Steiner E. High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study) a prospective study . Lancet. 358:2001;2026-2033.
11. Sniderman A.D., Cianflone K. Measurement of apoproteins time to improve the diagnosis and treatment of the atherogenic dyslipoproteinemias . Clin Chem. 42:1996;489-491.
12. Sniderman A.D., Pedersen T., Kjekshus J. Putting low-density lipoproteins at center stage in atherogenesis. Am J Cardiol. 79:1997;64-67.
13. Sniderman A.D., Scantlebury T., Cianflone K. Hypertriglyceridemic hyperapoB the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus . Ann Intern Med. 135:2001;447-459.
14. Otvos J. Measurement of triglyceride-rich lipoproteins by nuclear magnetic resonance spectroscopy. Clin Cardiol. 22:(6 suppl):1999;II21-II27.
15. Packard C.J. Understanding coronary heart disease as a consequence of defective regulation of apolipoprotein B metabolism. Curr Opin Lipidol. 10:1999;237-244.
16. Otvos J.D., Jeyarajah E.J., Bennett D.W., Krauss R.M. Development of a proton NMR spectroscopic method for determining plasma lipoprotein concentrations and subspecies distribution from a single, rapid measurement. Clin Chem. 38:1992;1632-1638.
17. Otvos J.D. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Rifai N., Warnick G.R., Dominiczak M.H., Handbook of Lipoprotein Testing. 2000;609-623 AACC Press, Washington, DC.
18. Kuller L.H., Arnold A., Tracy R., Otvos J., Burke G., Psaty B., Siscovick D., Freedman D.S., Kronmal R. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the Cardiovascular Health Study. Arteriosler Thromb Vasc Biol. 22:2002;1175-1180.
19. Austin M.A., Breslow J.L., Hennekens C.H., Buring J.E., Willett W.C., Krauss R.M. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 260:1988;1917-1921.
20. Stampfer M.J., Krauss R.M., Ma J., Blanche P.J., Holl L.G., Sacks F.M., Hennekens C.H. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 276:1996;882-888.
21. Griffin B.A., Freeman D.J., Tait G.W., Thomson J., Caslake M.J., Packard C.J., Shapherd J. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions relative contribution of small, dense LDL to coronary heart disease risk . Atherosclerosis. 106:1994;241-253.
22. Freedman D.S., Otvos J.D., Jeyarajah E.J., Barboriak J.J., Anderson A.J., Walker J.A. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol. 18:1998;1046-1053.
23. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol 2002;90:89-94.
24. Wilson H.M., Patel J.C., Russe D., Skinner E.R. Alterations in the concentration of an apolipoprotein-E-containing subfraction of plasma high-density lipoprotein in coronary heart disease. Clin Chim Acta. 220:1993;175-187.
25. Johansson J., Carlson L.A., Landou C., Hamsten A. High-density lipoproteins and coronary atherosclerosis a strong inverse relation with the largest particles is confined to normotriglyceridemic patients . Arterioscler Thromb. 11:1991;174-182.
26. Couture P., Otvos J.D., Cupples L.A., Wilson P.W.F., Schaefer E.J., Ordovas J.M. Association of the A-204C polymorphism in the cholesterol 7α-hydroxylase gene with variations in plasma low density lipoprotein cholesterol levels in the Framingham Offspring Study. J Lipid Res. 40:1999;1883-1889.
27. Robins S.J., Collins D., Wittes J.T., Papademetriou V., Deedwania P.C., Schaefer E.J., McNamara J.R., Kashyap M.L., Hershman J.M., Wexler L.F., Rubins H.B. Relation of gemfibrozil treatment and lipid levels with major coronary events. JAMA. 285:2001;1585-1591.
28. Williams P.T., Krauss R.M., Vranizan K.M., Stefanick M.L., Wood P.D.S., Lindgren F.T. Associations of lipoproteins and apolipoproteins with gradient gel electrophoresis estimates of high density lipoprotein subfractions in men and women. Arterioscler Thromb. 12:1992;332-340.
29. Rainwater D.L. Lipoprotein correlates with LDL particle size. Atherosclerosis. 148:2000;151-158.
30. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Adult Treatment Panel III . JAMA. 285:2001;2486-2497.
31. Grundy S.M. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol. 83:1999;25F-29F.